Hepatitis Diagnostic Tests Market To Reach $5.90 Billion By 2030

Hepatitis Diagnostic Tests Market Growth & Trends

The global hepatitis diagnostic tests market size is expected to reach USD 5.90 billion by 2030, registering a CAGR of 6.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. In the past decade, the burden of hepatitis A, B & C has significantly increased compared to that of type D & E. In addition, in emerging countries, around 90% of the children (below 10 years of age) are infected with type A virus as stated by the WHO reports. These reports also state that in 2016, around 71 million people were affected by hepatitis C and 257 million people were suffering from type B infection.

The non-government and government organizations play a vital role in increasing awareness of infectious diseases by conducting campaigns in order to deliver correct knowledge about the symptoms, condition, and detection techniques. Thereby, rendering a positive impact on the market growth owing to rising demand for diagnostic tests. Furthermore, the adoption of molecular biology techniques and other technologically advanced detection techniques are spurring market growth.

 Request a free sample copy or view report summary: Hepatitis Diagnostic Market Report

Hepatitis Diagnostic Tests Market Report Highlights

• The blood tests segment dominates the market with a revenue share of 52.1% in 2023, owing to their higher adoption as a first line of diagnosis.

• The liver function tests, a subtype of blood test hold a significant share of the market since these tests are the first line diagnostics and are prerequisite for further analytical examinations required to performed for confirmation of virus causing the disease

• North America dominated with the largest revenue share in 2023, owing to rising prevalence, various government initiatives creating awareness regarding rising incidences, and highly developed healthcare infrastructure

• Constant rise in the new cases of hepatitis is observed in Asia Pacific. Thus, this region is expected to witness fastest growth during the forecast period.

Hepatitis Diagnostic Tests Market Segmentation

Grand View Research has segmented the global hepatitis diagnostic tests market based on test, technology, end-use, and region:

Hepatitis Diagnostic Test Test Outlook (Revenue, USD Million, 2018 - 2030)

• Blood Tests

  • Liver Function Tests

  • Immunoassays

  • Nucleic Acid Tests

• Imaging Tests

• Liver Biopsy

Hepatitis Diagnostic Test Technology Outlook (Revenue, USD Million, 2018 - 2030)

• Enzyme-linked Immunosorbent Assay (ELISA)

• Rapid Diagnostic Test

• Polymerase Chain Reaction (PCR)

• Isothermal Nucleic Acid Amplification Technology (INAAT)

• Others

Hepatitis Diagnostic Test End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals & Diagnostic Labs

• Blood Banks

• Others

Hepatitis Diagnostic Test Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • Saudi Arabia

  • UAE

  • South Africa

  • Kuwait

List of Key Players in the Hepatitis Diagnostic Tests Market

• Abbott Laboratories

• Bio-Rad Laboratories Inc

• BioMerieux SA

• F. Hoffmann-La Roche AG

• Siemens Healthineers

• Diasorin S.p.A

• Qaigen

• Sysmex Corporation

• VWR International, LLC

• Hologic Inc